ABVC BioPharma receives $200,000 cash payment from OncoX

ABVC BioPharma (ABVC) announced the receipt of a $200,000 cash payment from OncoX BioPharma as part of its strategic licensing agreement for certain oncology-related products; this payment marks the first installment of $5M in potential licensing fees from OncoX. With this payment, the total accumulated cash payment ABVC has received from its three strategic partners for licensing various ABVC products is $546,000. ABVC and its subsidiaries BioLite Inc. and Rgene Corporation are each eligible to receive up to 10M OncoX shares, $5M cash payment, and royalties up to $50M after the product launches. The OncoX licensing agreement highlights both companies’ commitment to advancing breakthrough therapies in oncology.